Anatomy explorers have charted a new path myeloid cells use to access the brain. On 3 June in Neuron, scientists led by Lindsay Hohsfield and Kim Green, both at the University of California, Irvine, ...

On April 15, two years after Eisai requested a marketing license for lecanemab in Europe, the European Commission has greenlit its use. The biologic’s long path included an initial rejection from the ...

Their analysis of three large population studies found that age-adjusted prevalence has dropped by a whopping two-thirds over the last 40 years. In other words, every successive birth cohort has a ...

Of the 20,000+ human genes, none has greater influence on late-onset Alzheimer’s disease than APOE. But why do certain variants of this lipid transporter protect the brain, while others endanger it? A ...

Most Alzheimerologists agree that lecanemab and donanemab are a start, but insufficient to treat this disease. At the Clinical Trials in Alzheimer’s Disease conference, held last month in Madrid, ...

On September 26, 2024, the National Institute on Aging (NIA) announced that Masliah had been removed from his position as scientific director of the institute’s neuroscience division after a ...

The advisory committee voted 11 to 0 on both questions in favor of the approval of donanemab. The committee recognized, correctly I think, that the data supported a modestly favorable benefit to risk ...

Research over the last decade has shown that aggregated Aβ seeds can be transferred between people during rare medical procedures, sparking amyloidosis in the recipient. Could this result in ...

Not so long ago, a blood test for Alzheimer’s disease seemed a pipe dream. Now, after years of study, the field is awash with sensitive assays that signal the proteopathic culprits Aβ and tau ...

Fox added that peer-reviewed studies are needed to fully understand the sensitivity and specificity of the approach. One preprint, and findings presented at CTAD conferences in 2020 and 2021, suggest ...

The latest effort to rewrite the diagnostic criteria for Alzheimer’s disease has stirred more than a little controversy. While the proposed revisions have garnered praise from researchers for more ...

Current diagnostic options for PD include DaTscan SPECT to assess dopamine transporter activity, the Syn-One test to detect α-synuclein aggregates in a skin biopsy, or the SYNTap α-synuclein seed ...